What are the stages of Lyme disease and their respective treatments?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Stages of Lyme Disease and Their Respective Treatments

Lyme disease progresses through three distinct stages: early localized, early disseminated, and late disseminated, each requiring specific antibiotic treatments based on clinical manifestations and disease severity.

Stage I: Early Localized Infection (Days to Weeks)

Clinical Manifestations:

  • Erythema migrans (EM): Pathognomonic gradually expanding annular lesion >5 cm in diameter at the tick bite site 1
  • Associated symptoms: Fever, lymphadenopathy, myalgias, arthralgias 1
  • Occurs in approximately 70-80% of infected persons 1

Diagnosis:

  • Clinical diagnosis based on EM rash in endemic areas (no laboratory testing needed) 1
  • Serologic testing has low sensitivity (30-40%) during this early stage 1

Treatment:

  • Oral antibiotics for 10-14 days 2:
    • Doxycycline: 100 mg twice daily (first-line for adults and children ≥8 years)
    • Amoxicillin: 500 mg three times daily (preferred for children <8 years, pregnant women)
    • Cefuroxime axetil: 500 mg twice daily (alternative)
    • Azithromycin (second-line option)

Stage II: Early Disseminated Infection (Weeks to Months)

Clinical Manifestations:

  • Multiple EM lesions (hematogenous spread) 1
  • Borrelial lymphocytoma (bluish-red tumor-like skin infiltrate, often on ear lobe or nipple) 1
  • Neurologic involvement:
    • Facial nerve palsy (Bell's palsy)
    • Meningitis
    • Meningoradiculitis 1
  • Cardiac involvement (5% of cases):
    • Atrioventricular block
    • Myocarditis
    • Conduction disorders 1, 2

Diagnosis:

  • Two-tiered serologic testing: ELISA/IFA followed by Western immunoblot 1, 2
  • Sensitivity of 70-100% during this stage 1
  • Specificity >95% 1

Treatment:

  • For neurologic manifestations:

    • Facial nerve palsy without CSF abnormalities: Oral antibiotics for 14 days 2
    • Meningitis or radiculopathy: IV ceftriaxone 2g daily for 14 days (range 10-28 days) 2
  • For cardiac manifestations:

    • Parenteral antibiotics (IV ceftriaxone) 2
    • Hospitalization for symptomatic patients or those with advanced heart block 2
    • Temporary pacemaker for symptomatic bradycardia or high-grade AV block not responding to antibiotics 2

Stage III: Late Disseminated Infection (Months to Years)

Clinical Manifestations:

  • Arthritis: Recurrent large-joint arthritis, especially knee 1
  • Acrodermatitis chronica atrophicans (ACA): Bluish-red discoloration progressing to skin atrophy, associated with B. afzelii 1
  • Late neurologic manifestations (uncommon in US):
    • Peripheral neuropathy
    • Encephalopathy
    • Encephalomyelitis 1

Diagnosis:

  • Strong serologic reactivity with expanded Western blot IgG banding patterns 1
  • Synovial fluid analysis in arthritis cases shows mild-to-moderate inflammation 1
  • PCR of synovial fluid may provide additional diagnostic certainty in seropositive patients 1

Treatment:

  • For arthritis:

    • Initial treatment with oral antibiotics
    • For arthritis that has failed to improve or worsened: IV ceftriaxone 2g daily for 2-4 weeks 2
    • Refractory cases may require anti-inflammatory agents or surgical synovectomy 1
  • For late neurologic manifestations:

    • IV antibiotics (ceftriaxone, cefotaxime, or penicillin G) for 14-21 days 2

Important Clinical Considerations:

  • Antibody persistence: Antibodies often persist for months or years after successfully treated infection, so seroreactivity alone cannot be used as a marker of active disease 1
  • Post-Lyme disease syndrome: Some patients experience persistent symptoms after appropriate treatment that are not responsive to additional antibiotics 1, 2
  • The IDSA, AAN, and ACR do not recognize "chronic Lyme disease" as a valid diagnosis and recommend against prolonged antibiotic therapy 2
  • Geographic variations: B. burgdorferi sensu stricto predominates in the US, while B. afzelii and B. garinii are more common in Europe and Asia, affecting clinical manifestations 1, 3

Prophylaxis:

For high-risk tick bites meeting all criteria:

  • Identified Ixodes tick attached for ≥36 hours
  • Prophylaxis started within 72 hours of tick removal
  • Local infection rate of ticks with B. burgdorferi ≥20%
  • Single dose of doxycycline: 200 mg for adults, 4.4 mg/kg (max 200 mg) for children ≥8 years 2

Proper early diagnosis and appropriate antibiotic treatment are essential to prevent progression to later stages of Lyme disease and their associated complications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Lyme Disease Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Lyme borreliosis.

Nature reviews. Disease primers, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.